Clinical trials: H. Pylori Eradication Therapy, open to volunteers
- Condition H. Pylori Eradication Therapy
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Helicobacter Pylori Infection, Gastrointestinal Dysbiosis
Bacillus Probiotics With Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is a very common gastrointestinal disease that colonises the human gastric mucosa and is a primary risk factor for chronic gastritis, peptic ulcer disease, and gastric cancer.
- Conditions
- Helicobacter Pylori Infection, Gastrointestinal Dysbiosis, Antibiotic-associated Adverse Events
- Trial name
- NCT07827170
- Testing
- RO water, LiveSpo CLAUSY, LiveSpo DIA30
- Where
- Vietnam
- Volunteers
- 336 people
- Sponsor
- Anabio R&D
HELICOBACTER PYLORI INFECTIONS
The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple…
- Trial name
- NCT07606833
- Testing
- Anaprazole Sodium enteric-coated tablet, Esomeprazole magnesium enteric-coated tablets
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
H. Pylori Eradication Therapy
Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects
- Trial name
- NCT07875933
- Volunteers
- 414 people
- Sponsor
- Onconic Therapeutics Inc.